PharmGKB summary: very important pharmacogene information for RYR1

Pharmacogenet Genomics. 2016 Mar;26(3):138-44. doi: 10.1097/FPC.0000000000000198.

Authors

Maria L Alvarellos¹, Ronald M Krauss, Russell A Wilke, Russ B Altman, Teri E Klein

Affiliation

¹ Departments of aGenetics bBioengineering, Stanford University, Stanford cChildren's Hospital Oakland Research Institute and UCSF, Oakland, California dDepartment of Medicine, University of North Dakota, Fargo, North Dakota eIMAGENETICS, Sanford Healthcare, Sioux Falls, South Dakota, USA.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Genetic Predisposition to Disease
Genetic Variation
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
Malignant Hyperthermia / epidemiology
Malignant Hyperthermia / genetics*
Muscle, Skeletal / metabolism*
Muscular Diseases / chemically induced
Muscular Diseases / genetics
Pharmacogenetics
Ryanodine Receptor Calcium Release Channel / genetics*
Ryanodine Receptor Calcium Release Channel / metabolism

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Ryanodine Receptor Calcium Release Channel

Grants and funding